Cost-effectiveness model to evaluate 200-days vs 100-days treatment with valganciclovir prophylaxis to reduce cytomegalovirus disease in high-risk (D+/R-) kidney transplant recipient in Spain
Date issued
2011Journal title
TRANSPLANT INTERNATIONAL
Type of content
Publicación de congreso